First Trust NYSE Arca Biotechnology Index Fund (FBT)

NYSEARCA: FBT · Real-Time Price · USD
208.77
+4.51 (2.21%)
Apr 14, 2026, 4:00 PM EDT - Market closed
Assets$2.28B
Expense Ration/a
PE Ration/a
Shares Out11.30M
Dividend (ttm)n/a
Dividend Yieldn/a
Ex-Dividend Daten/a
Payout Frequencyn/a
Payout Ration/a
Volume60,217
Open204.71
Previous Close204.26
Day's Range204.71 - 209.42
52-Week Low150.22
52-Week High224.94
Beta0.70
Holdings32
Inception DateJun 19, 2006

About FBT

Fund Home Page

The First Trust NYSE Arca Biotechnology Index Fund is an exchange-traded index fund. The investment objective of the Fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE Arca Biotechnology Index.

Category Health
Stock Exchange NYSEARCA
Ticker Symbol FBT

Top 10 Holdings

39.94% of assets
NameSymbolWeight
Moderna, Inc.MRNA5.25%
United Therapeutics CorporationUTHR4.18%
Axsome Therapeutics, Inc.AXSM4.07%
Gilead Sciences, Inc.GILD4.06%
Alkermes plcALKS3.98%
Corcept Therapeutics IncorporatedCORT3.95%
Amgen Inc.AMGN3.81%
argenx SEARGX3.59%
Exelixis, Inc.EXEL3.55%
Krystal Biotech, Inc.KRYS3.50%
View More Holdings

Dividend History

Ex-DividendAmountPay Date
Dec 13, 2024$1.1726Dec 31, 2024
Sep 23, 2015$0.0197Sep 30, 2015
Jun 24, 2015$0.0649Jun 30, 2015
Mar 25, 2015$0.0476Mar 31, 2015
Dec 23, 2014$0.0524Dec 31, 2014
Jun 23, 2008$0.2697Jun 30, 2008
Full Dividend History

Performance

FBT had a total return of 37.32% in the past year, including dividends. Since the fund's inception, the average annual return has been 12.68%.

News

Here are the top-performing ETFs in first half of 2023 as crypto-related funds soar

Hello! This week's ETF Wrap looks at top performers in the first half of 2023, as well as flows, as stocks rally and crypto-related funds jump so far this year.

3 years ago - Market Watch

5 Top ETFs With Exposure To Biogen

For the first time in 18 years, there was a new treatment for Alzheimer's Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that can reduce the clinical dec...

Other symbols: BIIBBBHIBBPBEPKW
5 years ago - Benzinga

3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover

The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexio...

Other symbols: BBHPBE
5 years ago - Benzinga

Biotech ETFs at multi-week highs, extending winning streak

Biotechnology exchange-traded funds outperformed Tuesday as investors focused on next-generation solutions to the coronavirus and more. The ARK Genomic Revolution ETF was up 2.2% in the early afternoo...

Other symbols: BBHIBBXBI
5 years ago - Market Watch

Biotech ETFs at two-week highs on upbeat vaccine news

Biotech exchange-traded funds got a bounce Friday from bullish news on coronavirus treatments. The ALPS Medical Breakthroughs ETF , the ARK Genomic Revolution ETF , and the First Trust NYSE Arca Biote...

Other symbols: ARKGSBIO
5 years ago - Market Watch

Election History Says Buy Biotech Dip

Biotechnology exchange-traded funds were hot until they weren't. History indicates recent weakness in the previously high-flying group be a symptom of election year jitters and investors shouldn't ign...

6 years ago - Benzinga

Post-Pandemic Stars Could Align For This Biotech ETF

These days, it's not hard to find winners among health care exchange-traded funds and that's true of both established and rookie players.

6 years ago - Benzinga

Biotech stocks fall after Trump promises executive order drug prices

CNBC's Meg Tirrell reports on the dip in biotech stocks after President Donald Trump promised that an executive order on drug prices is coming.

7 years ago - CNBC Television

Is now the time to buy Nike? What about biotech? #AskHalftime

The "Halftime Report" traders take viewer questions on Nike and biotech.

Other symbols: IBBNKEXBI
7 years ago - CNBC Television